Please login to the form below

Not currently logged in
Email:
Password:

Double chin

This page shows the latest Double chin news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera. Company will add Kythera’ s double chin therapy Kybella to its portfolio. ... Botox manufacturer Allergan has extended its position in the growing cosmetic or 'aesthetic' pharmaceuticals

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Kythera bags FDA approval for double chin therapy. Comes as cosmetics industry sees major growth. ... The US FDA has approved the first drug to treat submental fat in adults - otherwise known as a double chin.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    fat (double chin). ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella for double chin (FDA approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    In addition, Five Prime could receive up to $300m in future development, regulatory and sales-based milestones per collaboration target, as well as tiered mid-single-digit rising to ... ATX-101 is a proprietary injectable formulation of a synthetic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics